Vir Biotechnology Announces Pricing of Public Offering of Common Stock - November 12, 2026

Vir Biotechnology (VIR) priced a public offering of 15M shares at $10 each, raising $150M. It granted underwriters a 30-day option for additional 2.25M shares. Closing is expected Nov 16, 2026. Leerink, Morgan Stanley, and Evercore ISI are bookrunners. The offering was filed with the SEC.

Original reporting
Published Nov 13, 2026, 6:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vir Biotechnology Announces Pricing of Public Offering of Common Stock - November 12, 2026 — source image
Decision brief

The 30-second read

$VIRBearishHigh
01

Why it matters

The $150 M raise adds cash to the balance sheet but introduces dilution; investors will watch how the capital is allocated.

02

Market read

Primary disclosure of a sizable secondary offering; short‑term price impact expected, with longer‑term implications tied to capital deployment.

03

What to watch

Potential strategic partnership or pipeline milestone that could be funded by the capital raise.

Relevance 8/10Novelty 8/10Timing: today

Background

Vir Biotechnology is a clinical‑stage biopharma focused on infectious diseases and oncology, with a pipeline that includes hepatitis delta and PRO‑XTEN® T‑cell engagers.

Company-level read

Ticker impact

$VIRBearishHigh confidence
Context

Vir Biotechnology announced pricing of a $150 million public offering of 15 M shares at $10 each, with a 30‑day over‑allotment option.

Expected impact

likely downward pressure as the market prices in dilution from the $150 M raise

Evidence & confidence

New capital raise of significant size (>$100 M) is a primary disclosure; dilution typically depresses price until proceeds are deployed.

Market effects

Biotech sector may see modest sell‑off as investors reassess dilution risk across similar small‑cap pipelines.

US biotech market may experience slight negative bias in the short term.

Limited to investors tracking US‑listed biotech offerings.

Counterpoint

If the proceeds fund high‑impact trials, the long‑term upside could outweigh short‑term dilution.

Key entities

  • Vir Biotechnology, Inc.

    Issuer of the public offering.

  • Leerink Partners, Morgan Stanley, Evercore ISI

    Book‑running managers for the offering.

Related articles

$VIRHigh

Why Vir Biotechnology shares are trading lower today

Vir Biotechnology (VIR) shares fell 18.8% after announcing a $150M public offering of 15M shares at $10 each. The stock closed at $9.96, down 17.7% from the prior close. The company is up 68% YTD but 26.9% below its 52-week high. The offering may dilute existing shares and pressure the stock price.

$VIRHighAI 8/10

Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale

Vir Biotechnology (VIR) shares dropped 10% after announcing a stock sale. The company plans to sell 15 million shares at $10 each, raising $150 million. Underwriters may buy an additional 2.25 million shares, potentially increasing total proceeds to $172.5 million. The deal is expected to close on Nov. 16, 2026, subject to customary conditions and expenses.